A Phase I Study of NMS-03597812 in People with Multiple Myeloma

Full Title

A Phase I Dose Escalation Study of NMS-03597812, a PERK inhibitor, in Adult Patients with Relapsed or Refractory Multiple Myeloma

Purpose

The purpose of this study is to find the highest dose of the investigational drug NMS-03597812 that can be given safely in people with multiple myeloma that continues to grow despite treatment. NMS-03597812 blocks a protein called PERK that can help multiple myeloma cells grow and survive. By blocking this protein, NMS-03597812 may slow or stop the growth of multiple myeloma. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

• Participants must have multiple myeloma that came back or continued to grow despite at least three or more regimens of treatment.
• The serious side effects of previous treatments should get better before patients can receive NMS-03597812.
• Patients must be able to walk and do routine activities for more than half of their normal waking hours.
• This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Hani Hassoun at 646-608-3718.